Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 19, 2023
Discovery & Translation

PROTAC using an alt. E3 ligase; plus lung-targeted mRNA COVID vaccine and more

BioCentury’s roundup of translational innovations
BioCentury | Apr 25, 2023
Product Development

KRAS’s next chapter: hitting the target’s active form 

Investors rewarded Revolution for preclinical KRAS (ON) data at AACR23, as a wave of dual KRAS (ON/OFF) inhibitors at the meeting gear up for the clinic
BioCentury | Mar 12, 2022
Discovery & Translation

Translational highlights to watch for at AACR

BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference
BioCentury | Aug 16, 2018
Distillery Therapeutics

Infectious disease

BioCentury | Feb 15, 2017
Distillery Therapeutics

Neurology

BioCentury | Nov 9, 2016
Distillery Therapeutics

Infectious disease

BioCentury | Jun 27, 2016
Company News

Ciclofilin, ContraVir Pharmaceuticals deal

BioCentury | Jul 13, 2015
Clinical News

Ciclofilin preclinical data

BioCentury | Dec 11, 2014
Distillery Therapeutics

Indication: Various

BioCentury | Dec 19, 2013
Distillery Therapeutics

Indication: Infectious disease

Items per page:
1 - 10 of 21